CanSino Biologics (HKG:6185) received approval from China's National Medical Products Administration to begin a clinical trial of its Td5cp combined vaccine in children aged four to five, according to a Monday Hong Kong bourse filing.
The trial will assess whether the vaccine can be used as a booster in children aged four to six, extending its current booster-use age range, which starts at 6 years.
The vaccine is designed to protect against tetanus, diphtheria and pertussis, also known as whooping cough. The company said the proposed expansion aims to address a gap in preschool booster immunization and restore antibody levels to a protective range.